Investor Relations We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology. Email Alerts Investors: Overview Press Releases Events and Presentations Financials & Filings Stock Information Investor FAQs Contact Us Events Presentations LPCN 2401 Phase 2 clinical study results Thursday, April 11, 2024 8:30am EDT Listen to the Webcast